Use of the blood infection biomarker procalcitonin as a guide to prescribing antibiotics led to lower antibiotic exposure and side effects, as well as a lower mortality rate in individuals with acute respiratory infections, based on findings of a meta-analysis.
The paediatric dosing of intravenous zanamivir has a safety profile that is consistent with that expected in a population of children hospitalized for severe or progressive influenza, with majority achieving clinical improvement during the treatment course, according to a study.
Treatment with a ribavirin-free regimen of coformulated glecaprevir plus pibrentasvir appears to yield a high rate of sustained virologic response in hepatitis C virus-infected patients with advanced chronic kidney disease, while having an acceptable safety profile, according to the EXPEDITION-4 trial.
Patients with acute-on-chronic liver failure (ACLF) who fulfil both APASL* and EASL** criteria have an elevated risk of liver disease-related mortality, according to a retrospective single-centre study conducted in Singapore. The findings also revealed the factors associated with a poorer prognosis.
New drug applications approved by US FDA as of 1 - 15 November 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
In patients infected with Helicobacter pylori, long-term use of proton pump inhibitors is associated with an increased risk of gastric cancer even after treatment for the infection, a recent population-based study has shown.
The risks of hepatocellular carcinoma (HCC) and death/transplantation in chronic hepatitis B virus infection appear to be greater in untreated immune-tolerant-phase patients than in treated immune-active-phase patients, a study has found.
Self-administered, once-weekly isoniazid and rifapentine to treat latent tuberculosis infection is feasible in the United States, and this treatment can be used in similar settings when direct observation is not viable, suggests a new study.
In patients with underlying heart failure (HF) or chronic obstructive pulmonary disease (COPD), concurrent episodes of community-acquired pneumonia increase the risk of disease exacerbations, such as short-term cardiac complications and respiratory failure, a recent study has shown.
Use of clarithromycin in the outpatient setting appears to be associated with long-term increases in mortality, a retrospective study has found. Additionally, erythromycin yields a similar, albeit smaller, increase in the said risk.
In this issue of MIMS Anti-Infective Supplement, we bring you clinical updates related to combating infectious diseases, and also a symposium highlight in conjunction with the launch of ceftolozane/tazobactam (Zerbaxa; Merck Sharp & Dohme Sdn Bhd) in Malaysia.